Immunai strikes $85M deal with AstraZeneca to develop new IBD drug target
AI biotech expands partnership after uncovering novel immune target with its machine learning platform.
Thursday, October 16, 2025
YEDA Technology Transfer from the Weizmann Institute of Science
Yeda Research and Development